L’Intelligenza Artificiale (AI) sta trasformando il settore medico-sanitario, con un impatto destinato a crescere significativamente nei prossimi anni.
AstraZeneca will present new clinical and real-world data in multiple haematological conditions at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA, 9 to 12 December 2023.
843.6 million people worldwide are living with chronic kidney disease (CKD), a progressive and potentially fatal condition. Yet, the majority remain undiagnosed and untreated.
Oltre ai dati raccolti e diffusi negli studi registrativi, sempre più attenzione è posta nei confronti di quelli provenienti dalla real-world evidence. Ovvero: dall’esperienza clinica di tutti i giorni, in cui i pazienti non sono selezionati e dunque il target a cui viene somministrato un farmaco risulta più eterogeneo.
Data covering almost 30 million individuals show continued burden of disease;
immunocompromised individuals comprise approximately one quarter of all COVID-19
hospitalisations, ICU admissions and deaths.
Real-world data from INFORM study demonstrate increased risk of severe COVID-19
outcomes among all individuals with immunocompromising conditions
and highlight need for additional protection.
FluMist Quadrivalent data support the potential for a self-administered influenza vaccine to expand access to an important tool for prevention.
AstraZeneca’s real-world evidence (RWE) ZORA study shows the negative consequences of reducing or discontinuing life-saving renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK).
